Suppr超能文献

生物治疗制剂中聚山梨酯的降解:现有根本原因的鉴定和讨论。

Polysorbate degradation in biotherapeutic formulations: Identification and discussion of current root causes.

机构信息

Boehringer Ingelheim Pharma GmbH & Co. KG, Innovation Unit, PDB, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany.

Boehringer Ingelheim Pharma GmbH & Co. KG, Innovation Unit, PDB, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany.

出版信息

Int J Pharm. 2018 Dec 1;552(1-2):422-436. doi: 10.1016/j.ijpharm.2018.10.008. Epub 2018 Oct 6.

Abstract

Biotherapeutic protein formulations are often high concentration liquid protein solutions, which are required to be stable under pharmaceutically relevant storage conditions and presence of external stress. Non-ionic detergents like polysorbate have been the most commonly used detergent to maintain formulation stability. Recently, particle formation in polysorbate containing biotherapeutic formulations has arisen as a major quality concern and potential patient risk factor. In this review, we provide a general overview into (i) degradation of polysorbates, (ii) polysorbate analytics, (iii) particle formation induced by polysorbate degradation and root causes thereof, (iv) particle composition and (v) various influencing factors that might lead to particle formation. Consequently, we explore the role of polysorbate degradation in particle formation. Additionally, various degradation pathways and the current discussed root causes are reviewed.

摘要

治疗性蛋白制剂通常为高浓度的液体蛋白溶液,其在相关药用储存条件和外部应激下必须保持稳定。非离子型去污剂如聚山梨酯是最常用来维持制剂稳定性的去污剂。最近,聚山梨酯存在的治疗性蛋白制剂中出现颗粒形成的现象,这已成为一个主要的质量关注点和潜在的患者风险因素。在这篇综述中,我们提供了一个总体概述:(i)聚山梨酯的降解,(ii)聚山梨酯分析,(iii)聚山梨酯降解诱导的颗粒形成及其根本原因,(iv)颗粒组成,以及(v)可能导致颗粒形成的各种影响因素。因此,我们探讨了聚山梨酯降解在颗粒形成中的作用。此外,还综述了各种降解途径和目前讨论的根本原因。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验